 | • レポートコード：MRC2301A157 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、231ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査資料では、2021年に2,188.18百万ドルであった世界の免疫組織化学（IHC）市場規模が、2022年には2,419.03百万ドルになり、その後CAGR 10.72％で拡大して2027年までに4,032.74百万ドルに達すると予想しています。当書は、免疫組織化学（IHC）の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（抗体、機器、キット、試薬）分析、用途別（診断、薬物検査、フォレンジック）分析、エンドユーザー別（学術・研究機関、CRO、法医学研究所、病院・診断研究所、医薬品・バイオ医薬品会社）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめています。なお、当書に掲載されている企業情報には、Abcam PLC、Agilent Technologies, Inc.、Bio SB, Inc.、Bio-Rad Laboratories, Inc.、Biocare Medical, LLC、Biogenex Laboratories、Candor Bioscience GmbH、Cell Signaling Technology, Inc.、Danaher Corporationなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の免疫組織化学（IHC）市場規模：製品別 - 抗体の市場規模 - 機器の市場規模 - キットの市場規模 - 試薬の市場規模 ・世界の免疫組織化学（IHC）市場規模：用途別 - 診断における市場規模 - 薬物検査における市場規模 - フォレンジックにおける市場規模 ・世界の免疫組織化学（IHC）市場規模：エンドユーザー別 - 学術・研究機関における市場規模 - CROにおける市場規模 - 法医学研究所における市場規模 - 病院・診断研究所における市場規模 - 医薬品・バイオ医薬品会社における市場規模 ・世界の免疫組織化学（IHC）市場規模：地域別 - 南北アメリカの免疫組織化学（IHC）市場規模 アメリカの免疫組織化学（IHC）市場規模 カナダの免疫組織化学（IHC）市場規模 ブラジルの免疫組織化学（IHC）市場規模 ... - アジア太平洋の免疫組織化学（IHC）市場規模 日本の免疫組織化学（IHC）市場規模 中国の免疫組織化学（IHC）市場規模 インドの免疫組織化学（IHC）市場規模 韓国の免疫組織化学（IHC）市場規模 台湾の免疫組織化学（IHC）市場規模 ... - ヨーロッパ/中東/アフリカの免疫組織化学（IHC）市場規模 イギリスの免疫組織化学（IHC）市場規模 ドイツの免疫組織化学（IHC）市場規模 フランスの免疫組織化学（IHC）市場規模 ロシアの免疫組織化学（IHC）市場規模 ... - その他地域の免疫組織化学（IHC）市場規模 ・競争状況 ・企業情報 |
The Global Immunohistochemistry Market size was estimated at USD 2,188.18 million in 2021 and expected to reach USD 2,419.03 million in 2022, and is projected to grow at a CAGR 10.72% to reach USD 4,032.74 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Immunohistochemistry to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Antibodies, Equipment, Kits, and Reagents. The Antibodies is further studied across Primary Antibodies and Secondary Antibodies. The Equipment is further studied across Slide Scanners, Slide Staining Systems, Tissue Microarrays, and Tissue Processing Systems. The Reagents is further studied across Blocking Sera and Reagents, Chromogenic Substrates, Diluents, Fixation Reagents, Histological Stains, Organic Solvents, Proteolytic Enzymes, and Stabilizers.
Based on Application, the market was studied across Diagnostics, Drug Testing, and Forensic. The Diagnostics is further studied across Autoimmune Diseases, Cancer, Cardiovascular Diseases, Diabetes Mellitus, Infectious Diseases, and Nephrological Diseases.
Based on End-user, the market was studied across Academic & Research Institutes, CROs, Forensic Labs, Hospitals & Diagnostic Laboratories, and Pharma & Biopharma Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Immunohistochemistry market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Immunohistochemistry Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Immunohistochemistry Market, including Abcam PLC, Agilent Technologies, Inc., Bio SB, Inc., Bio-Rad Laboratories, Inc., Biocare Medical, LLC, Biogenex Laboratories, Candor Bioscience GmbH, Cell Signaling Technology, Inc., Danaher Corporation, Diagnostic BioSystems Inc., Eagle Biosciences, Inc., F. Hoffmann-La Roche AG, GenomeMe, Merck KGaA, Miltenyi Biotec, NeoGenomics Laboratories, Inc., Perkinelmer, Inc., Sakura Finetek Japan Co.,Ltd., Sino Biological Inc., and Thermo Fisher Scientific, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Immunohistochemistry Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Immunohistochemistry Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Immunohistochemistry Market?
4. What is the competitive strategic window for opportunities in the Global Immunohistochemistry Market?
5. What are the technology trends and regulatory frameworks in the Global Immunohistochemistry Market?
6. What is the market share of the leading vendors in the Global Immunohistochemistry Market?
7. What modes and strategic moves are considered suitable for entering the Global Immunohistochemistry Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Extensive prevalence of chronic diseases such as cancer and autoimmune diseases among population
5.1.1.2. Development of technologically advanced IHC solutions coupled with rising product approvals
5.1.1.3. Increasing drug discoveries and development activities
5.1.2. Restraints
5.1.2.1. Capital intensive setup and dearth of specificity in IHC solutions
5.1.3. Opportunities
5.1.3.1. Merging collaborations between pharmaceutical companies and players involved in IHC development
5.1.3.2. Growing demand for personalized/customized medicine
5.1.4. Challenges
5.1.4.1. Concerns pertinent to product failure and shortage of skilled professionals
5.2. Cumulative Impact of COVID-19
6. Immunohistochemistry Market, by Product
6.1. Introduction
6.2. Antibodies
6.3.1. Primary Antibodies
6.3.2. Secondary Antibodies
6.3. Equipment
6.4.1. Slide Scanners
6.4.2. Slide Staining Systems
6.4.3. Tissue Microarrays
6.4.4. Tissue Processing Systems
6.4. Kits
6.5. Reagents
6.6.1. Blocking Sera and Reagents
6.6.2. Chromogenic Substrates
6.6.3. Diluents
6.6.4. Fixation Reagents
6.6.5. Histological Stains
6.6.6. Organic Solvents
6.6.7. Proteolytic Enzymes
6.6.8. Stabilizers
7. Immunohistochemistry Market, by Application
7.1. Introduction
7.2. Diagnostics
7.3.1. Autoimmune Diseases
7.3.2. Cancer
7.3.3. Cardiovascular Diseases
7.3.4. Diabetes Mellitus
7.3.5. Infectious Diseases
7.3.6. Nephrological Diseases
7.3. Drug Testing
7.4. Forensic
8. Immunohistochemistry Market, by End-user
8.1. Introduction
8.2. Academic & Research Institutes
8.3. CROs
8.4. Forensic Labs
8.5. Hospitals & Diagnostic Laboratories
8.6. Pharma & Biopharma Companies
9. Americas Immunohistochemistry Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Immunohistochemistry Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Immunohistochemistry Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abcam PLC
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Agilent Technologies, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bio SB, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bio-Rad Laboratories, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Biocare Medical, LLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Biogenex Laboratories
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Candor Bioscience GmbH
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cell Signaling Technology, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Danaher Corporation
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Diagnostic BioSystems Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eagle Biosciences, Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. F. Hoffmann-La Roche AG
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. GenomeMe
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Merck KGaA
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Miltenyi Biotec
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. NeoGenomics Laboratories, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Perkinelmer, Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sakura Finetek Japan Co.,Ltd.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sino Biological Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Thermo Fisher Scientific, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing